PALO ALTO, California and
STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (NYSE: VAR)
announced that the Karolinska University Hospital Solna in
Sweden is the first hospital in
Scandinavia to deliver High Dose Rate (HDR) brachytherapy
treatments using the new Bravos™ afterloader system.
Bravos is an advanced integrated system designed to improve the
patient and clinic experience by simplifying brachytherapy
treatments and provide greater workflow efficiency.
HDR brachytherapy involves delivering radiotherapy by
temporarily placing a small radioactive source directly into the
tumor or other targeted area. Using the Bravos afterloader,
clinicians are able to position the radioactive source in a needle,
catheter or tumor-specific applicator following a pattern that has
been designed to create a highly conformal dose distribution within
or on the surface of the patient's anatomy. Once the treatment is
completed, the source safely returns to the Bravos
afterloader.
To simplify the treatment process, the Bravos afterloader
features intuitive color-coded indicator lights that confirm
correct applicator connections. To enrich the patient experience, a
touchscreen provides easy access to patient treatment information
directly on the afterloader, eliminating the need for the clinician
to leave the room to retrieve patient and treatment
information.
To help increase efficiency of the treatment process, Bravos
features a pre-treatment checklist. Like surgical procedures, the
customizable checklist allows the clinician to set a review process
including a time-out for patient safety and e-signatures for speed
and accuracy.
"In addition to equipping its centers with Varian medical linear
accelerators, we applaud Karolinska University Hospital for taking
this step to bring Varian's latest and most advanced brachytherapy
technology to cancer patients and are thrilled a facility of this
stature has chosen Varian," said Jean-Luc
Devleeschauwer, president, Varian Oncology Systems EMEIA.
"At Varian, we have done the groundwork to understand the needs of
patients and clinicians to help simplify the brachytherapy
treatment process. The result is Bravos and it is another important
step toward advancing the treatment and care for cancer patients
globally."
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 9,200 employees across 70 countries keep
the patient and our clinical partners at the center of our thinking
as we power new victories in cancer care. Because, for cancer
patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow @VarianMedSys
on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com